0000000000661114

AUTHOR

Domenico Labriola

showing 2 related works from this author

Hysteroscopic and ultrasonographic evaluation of ulipristal acetate treatment for symptomatic myomas in premenopausal women: a prospective study

2020

Objective: This study aimed to analyze the effects of a six-month therapy with ulipristal acetate (UPA) on myoma size and endometrial thickness in premenopausal women. Material and methods: Seventy-four women undergoing conservative therapy with UPA were enrolled for this study. All women underwent transvaginal ultrasound evaluation to assess the endometrial thickness, and the number and size of myomas at the beginning and after six months. Hysteroscopy and biopsy were performed after six months, if necessary. Results: After six months of treatment, sonographic examination showed a statistically significant (p <.05) reduction of the size of the largest myoma (56.3 ± 5.1 vs. 31.7 ± 10.1 m…

medicine.medical_specialtyNorpregnadienesUterine fibroidsHysteroscopy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePregnancyUlipristal acetateSelective progesterone receptor modulatorulipristal acetatemedicineHumansProspective Studiesuterine fibroidsProspective cohort studyGynecologyLeiomyomamedicine.diagnostic_testbusiness.industryMetrorrhagiaMyomaselective progesterone receptor modulatormedicine.diseaseMyomachemistryHysteroscopy030220 oncology & carcinogenesisUterine NeoplasmsFemale030211 gastroenterology & hepatologySurgerymedicine.symptombusinessmetrorrhagia
researchProduct

Efficacy of Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic Review and Meta-Analy…

2019

Background and Objectives: Hot flushes and sleep disturbances are the most common vasomotor symptoms (VMS) reported by postmenopausal women. Hormonal treatment is to date referred to as the gold standard approach but not suitable for all the patients. Alternative treatments are needed in case of a contraindication to menopausal hormone therapy (MHT), adverse side effects, and poor compliance. Paroxetine salt is the only nonhormonal medication approved by the US Food and Drug Administration for the management of VMS. Nonetheless, few trials with low consensus are available about this topic. In this review, we aimed to evaluate the efficacy of low-dose paroxetine therapy in the treatment of v…

Sleep Wake Disordersmedicine.medical_specialtyMedicine (General)Ovariectomyvasomotor symptomsefficacymenopauseReviewPlacebosleep disturbanceslaw.inventionR5-920Randomized controlled triallawInternal medicinemedicineHumanshot flusheAdverse effectContraindicationRandomized Controlled Trials as TopicVasomotorbusiness.industryGeneral Medicinemedicine.diseasesleep disturbanceParoxetineMenopausePostmenopauseParoxetineMeta-analysisefficacy; hot flushes; menopause; paroxetine; sleep disturbances; vasomotor symptomsHot FlashesFemalehot flushesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugMedicina
researchProduct